10-K: Definitive Healthcare Reports 4% Revenue Decline, Impairments

Definitive Healthcare Corp. reported a 4% decrease in revenue for fiscal year 2025, alongside substantial goodwill impairment charges and a decline in customer retention, attributing challenges to macroeconomic conditions and sales execution issues.

Summary

• Revenue decreased by $10.7 million, or 4%, to $241.5 million in 2025 from $252.2 million in 2024.
• Net loss for 2025 was $199.3 million, an improvement from $591.4 million in 2024, primarily due to lower goodwill impairment charges.
• Goodwill impairment charges totaled $196.1 million in 2025, following $688.9 million in 2024 and $287.4 million in 2023.
• Total customer count decreased to approximately 2,330 as of December 31, 2025, from 2,500 as of December 31, 2024.
• Enterprise Customer accounts decreased by eight to 511 as of December 31, 2025, from 519 as of December 31, 2024.
• Net Dollar Retention Rate (NDR) for Enterprise Customers was 85% in 2025, down from 90% in 2024.
• NDR for all customers over $17,500 ARR was 82% in 2025, down from 85% in 2024.
• Operating expenses decreased by $500.7 million, or 55%, in 2025, mainly due to lower goodwill impairment charges.
• Cash and cash equivalents increased to $163.6 million as of December 31, 2025, from $105.4 million in 2024.
• Total remaining performance obligations (cRPO + non-current) decreased to $240.5 million as of December 31, 2025, from $293.7 million in 2024.
• The company completed the acquisition of Carevoyance for $13.7 million in cash in January 2024 and Populi for $54.1 million in July 2023.
• A stock repurchase program of up to $100.0 million was authorized in November 2024 and expired on December 31, 2025, with $49.5 million in repurchases during 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report, marked by declining revenue, customer base contraction, and reduced retention rates. While net loss improved due to lower impairment, the underlying operational metrics and negative future guidance suggest ongoing challenges and a need for significant strategic adjustments to restore growth.

Positives

• Net loss significantly reduced to $199.3 million in 2025 from $591.4 million in 2024, primarily due to lower goodwill impairment charges.
• Cash and cash equivalents increased to $163.6 million as of December 31, 2025, from $105.4 million in 2024.
• The company believes its cash flow from operations, revolving credit facility, and available cash will be sufficient to meet liquidity needs for at least the next twelve months.
• Implemented restructuring plans in 2023 and 2024 to reduce operating costs and improve operating margins.
• Received one-time credits during fiscal year 2025 from renegotiations on existing data contracts, contributing to a net decrease in hosting fees and data subscription costs.
• Maintained effective internal control over financial reporting as of December 31, 2025, as audited by Deloitte & Touche LLP.
• The company's EU subsidiary, Monocl AB, operates under a Swedish publishing certificate, providing an exemption from certain core provisions of the EU GDPR.

Negatives

• Revenue decreased by 4% ($10.7 million) in 2025 compared to 2024, driven by lower subscription revenue.
• Total customer count decreased to approximately 2,330 as of December 31, 2025, from 2,500 in 2024.
• Enterprise Customer accounts decreased by eight to 511 as of December 31, 2025, from 519 in 2024.
• Net Dollar Retention Rate (NDR) for Enterprise Customers declined to 85% in 2025 from 90% in 2024.
• NDR for all customers over $17,500 ARR declined to 82% in 2025 from 85% in 2024.
• Goodwill impairment charges of $196.1 million were recorded in 2025, following $688.9 million in 2024 and $287.4 million in 2023, indicating a significant loss of asset value.
• Total remaining performance obligations decreased to $240.5 million as of December 31, 2025, from $293.7 million in 2024.
• Sales execution challenges in fiscal year 2024, due to changes in the go-to-market team, impacted new customer acquisition and upsell to existing customers in 2025 and are expected to continue into 2026.
• Experienced significant management turnover, including a new CFO and the elimination of the COO position.
• Macroeconomic conditions have led to heightened customer churn, particularly for smaller customers and in the Life Sciences market, and have elongated deal cycles.
• Gross profit margin is expected to decrease in 2026 due to revenue declines and a largely fixed cost structure, compounded by non-recurring one-time credits in 2025.
• The company is engaged in litigation regarding the Populi earn-out, disputing additional consideration claimed by former equity holders.
• The company's ability to obtain additional liquidity on reasonable terms or at all is not assured, especially with high interest rates and capital market volatility.

Risks

• Inability to generate sales or decline in demand for the platform could materially adversely affect business.
• Highly competitive market, with large, well-funded organizations developing internal technologies, leading to potential pricing pressures and reduced profit margins.
• Failure to respond to advances in healthcare commercial intelligence (including AI and LLMs) could result in competitors surpassing the platform's depth, breadth, or accuracy.
• Inability to obtain and maintain accurate, comprehensive, or reliable data could reduce demand for the platform and lead to customer dissatisfaction or legal claims.
• Recent growth rates may not be indicative of future growth, and the company may not sustain profitability as investments increase.
• Loss of access to data providers could negatively impact the platform and business operations.
• Information technology systems or data, or those of third parties, being compromised could lead to regulatory investigations, litigation, fines, business disruptions, and reputational harm.
• Security breaches or unauthorized access to data could lead to a perception of insecurity, reduced customer use, and significant liabilities.
• The use of AI and its integration with products may not be successful and could present business, compliance, and reputational challenges, including flawed algorithms, biased data, ethical issues, and competitive harm.
• Failure to offer optimal pricing and packaging of solutions could negatively impact growth and competitiveness.
• Reliance on third-party cloud providers means any disruption in their operations would adversely affect the business.
• Longer and more expensive sales cycles for larger Enterprise Customers, with increased competition and complex due diligence.
• Failure to provide high-quality customer experience could harm business and reputation, especially with a growing customer base.
• Misuse of the platform by customers or unauthorized parties could harm relationships, expose to litigation, or damage reputation.
• Acquisitions and investments may not realize expected benefits, prove difficult to integrate, disrupt business, or dilute stockholder value.
• Failure to maintain adequate operational and financial resources, especially with rapid growth, could hinder business plan execution and customer satisfaction.
• Dependence on executive officers and key employees, with loss or inability to attract talent posing a material adverse effect.
• Failure to protect and maintain the brand could harm reputation and ability to attract/retain customers.
• Factors adversely affecting the healthcare ecosystem (e.g., health reform, consolidation, regulatory changes, economic downturns) could negatively impact demand for solutions.
• Overestimation of the total addressable market could limit future growth rate.
• Negative effects from changes in search engine algorithms or other traffic-generating arrangements.
• International operations expose the company to inherent risks in foreign markets.
• Failure to raise additional capital or generate sufficient cash flows could reduce ability to compete.
• Internal restructuring activities may not achieve expected benefits and could strain workforce or divert management attention.
• Catastrophic events and geopolitical/trade tensions (e.g., Russia-Ukraine war, Middle East instability) could disrupt business.
• Use of open-source software carries risks of non-compliance with licenses, potential litigation, and security vulnerabilities.
• Reliance on third-party subscription and payment processing systems exposes the company to disruption risks.
• Stringent and evolving U.S. and foreign data privacy and security laws (e.g., HIPAA, CCPA, GDPR) and contractual obligations pose compliance challenges and potential liabilities.
• Legal challenges against the Swedish publishing certificate for Monocl AB could invalidate its GDPR exemption.
• Regulatory and legislative developments related to AI could adversely affect its use in products and expose the company to legal risks.
• Unanticipated changes in effective tax rate and additional tax liabilities may impact financial results.
• Requirement to collect sales or other related taxes in jurisdictions where not historically done could harm business.
• Deferred revenue may not be accurate indicators of future financial results due to contract term variability.
• Downturns in new sales and renewals are not immediately reflected in full in results of operations.
• Significant goodwill and intangible assets on the balance sheet are subject to impairment, which has occurred in the past and could recur.
• Level of indebtedness could limit ability to borrow, require substantial cash flow for payments, and increase vulnerability to adverse conditions.
• As a holding company, dependence on distributions from Definitive OpCo to pay dividends, taxes, and TRA obligations.
• TRA confers benefits to TRA Parties that may not benefit Class A common stock holders to the same extent, and payments can be substantial and accelerated.
• No reimbursement for TRA payments if tax benefits are disallowed.
• Risk of being deemed an investment company under the 1940 Act.
• Future offerings of debt or equity securities may dilute Class A common stock and adversely affect market price.
• Failure to realize anticipated long-term stockholder value of stock repurchase programs or failure to repurchase may negatively impact stock price.
• Certain directors and stockholders have no obligation to present business opportunities and may compete.
• Quarterly results may fluctuate significantly due to seasonality and other factors, leading to stock price decline.
• Market price and trading volume of Class A common stock has been and may continue to be volatile.
• Sales of substantial amounts of Class A common stock in public markets could negatively affect price.
• Significant costs to comply with public company laws and regulations.
• Concentration of ownership among executive officers, directors, and principal stockholders may prevent new investors from influencing decisions.
• Delaware law and organizational documents may impede or discourage a takeover.
• Claims for indemnification by directors and officers may reduce available funds.
• Designation of Delaware Court of Chancery and federal district courts as exclusive forums limits stockholders' ability to choose forums.
• Ability to issue preferred stock may deter takeover attempts.

Future Outlook

The company expects revenue to decline in 2026 compared to 2025, and gross profit margin is also anticipated to decrease in 2026 due to revenue declines and a largely fixed cost structure, compounded by non-recurring one-time credits received in 2025. The company will continue to monitor and mitigate risks related to changes in the healthcare claims data market and macroeconomic conditions.

Management Comments

• We believe any company selling or competing within the healthcare ecosystem is a potential customer for us and contributes to our estimated current total addressable market of over $11 billion and our serviceable addressable market of approximately $7 billion.
• We have identified more than 100,000 potential customers that we believe could benefit from our platform.
• Late in 2025, we began seeing modest signs of improvement in the macroeconomic backdrop, with healthier demand trends, more normalized procurement cycles, improving customer retention dynamics, and increased visibility into customer budgets, all of which are encouraging signs we will continue to monitor.
• We worked throughout 2025 to mitigate potential risk through renegotiation of select existing agreements and the addition of new data sources and will continue to do so in 2026.
• We believe that our core technologies and ongoing innovation represent a significant competitive advantage for us, and we continue to invest in systems optimization and product improvements for our customers, enhance our software development team and invest in automation and AI to drive higher quality data and deeper insights.
• We believe that our cash flow from operations, availability under the 2021 Credit Agreement and available cash and cash equivalents and short-term investments will be sufficient to meet our liquidity needs for at least the next twelve months.

Industry Context

StockSavvy.ai notes that Definitive Healthcare operates in a highly competitive and fragmented healthcare data and analytics market. The company's challenges with customer churn and declining Net Dollar Retention, particularly in the Life Sciences segment, reflect broader macroeconomic headwinds impacting business spending across industries. The continued investment in AI and data science is consistent with industry trends towards advanced analytics, but the company must effectively differentiate its proprietary intelligence against both legacy providers like Clarivate and IQVIA, and emerging niche players such as Komodo Health, to regain market share and improve growth.

Comparison to Industry Standards

• The company competes with legacy raw claims data providers such as Clarivate, IQVIA, and Symphony Health, emerging point solution players like AcuityMD and MedScout, niche healthcare specialists including Komodo Health, H1 Healthcare, Trella Health, and Trilliant Health, ecosystem players like SG2 and Veeva, and horizontal go-to-market intelligence platforms such as ZoomInfo, LinkedIn, and Dun & Bradstreet.
• The company believes no competitor matches its breadth of data and intelligence solutions or offers as comprehensive and accurate a commercial intelligence platform.
• Key competitive factors in the market include depth, breadth, and accuracy of healthcare-specific commercial intelligence, healthcare subject matter expertise, AI and data science capabilities, ease of use and deployment, and data privacy and security.

Management Changes

Corporate Governance

Legal Proceedings

• Litigation with former Populi equity holders regarding the earn-out for the 2024 performance period, where they assert a higher payout tier is due, which the company disputes. A contingent consideration liability of $3.0 million is recorded as of December 31, 2025.
• Subject to various other legal proceedings, claims, and governmental inspections, audits, or investigations that arise in the ordinary course of business, which management believes would not have a material adverse effect.

Related Party Transactions

• Recorded revenue from related parties (entities affiliated with Sponsors and Board members) of $0.7 million in 2025, $0.9 million in 2024, and $1.4 million in 2023.
• Associated receivables for these transactions were nil at December 31, 2025, and $0.2 million at December 31, 2024.
• Paid $2.5 million in 2025 and $2.1 million in 2024 to related parties for transactions in the ordinary course of business.
• Payables to related parties amounted to $0.2 million at December 31, 2025.

Stakeholder Impact

• Shareholders: Negative impact from declining revenue, customer churn, reduced NDR, and significant goodwill impairment charges. Stock repurchase program aims to enhance long-term value but may not offset declines. Potential dilution from future equity offerings.
• Employees: Restructuring plans in 2023 and 2024 resulted in global headcount reductions (approx. 100 in 2023, 150 in 2024), leading to loss of institutional knowledge and potential morale issues. Management changes also occurred.
• Customers: Macroeconomic conditions led to heightened churn, longer deal cycles, and deferred purchasing decisions. Sales execution challenges impacted new customer acquisition and upsells.
• Creditors: The company's level of indebtedness and ability to meet financial covenants are monitored, with a new Term Facility and Revolving Credit Facility maturing in 2030.
• Suppliers/Data Providers: Changes in the healthcare claims data market, including pricing and use terms, may negatively impact acquisition costs. The company is renegotiating agreements and adding new data sources.

Next Steps

• Redefine core values and embed them throughout the organization in 2026.
• Establish a DefinitiveCares Committee in 2026 to guide employee-led initiatives and engagement.
• Continue to monitor and mitigate potential risks related to changes in the healthcare claims data market in 2026.
• Continue to invest in sales and marketing efforts and develop new use cases for the platform to acquire new customers.
• Expand relationships with existing customers by adding functionality and expanding use-cases across departments.
• Continue to innovate and expand the platform through organic investments in engineering and R&D, and evaluate selective strategic acquisitions.
• Monitor for potential goodwill impairment should indicators arise in 2026.
• Continue to evaluate the Populi earn-out litigation and adjust the estimated fair value of the contingent consideration liability as necessary.

Key Dates

Recommendation

The filing presents a concerning picture with a 4% revenue decline, significant customer churn, and a notable drop in Net Dollar Retention Rates. The recurring and substantial goodwill impairment charges over three years indicate a persistent overvaluation of acquired assets and a fundamental challenge in the business model or market perception. Management's explicit guidance for further revenue decline and gross margin compression in 2026, coupled with ongoing macroeconomic headwinds and sales execution issues, suggests a deteriorating operational environment. While cost-cutting measures and a stock repurchase program are in place, they appear insufficient to counteract the negative trends. Investors should consider selling to mitigate further potential losses given the negative trajectory and lack of clear positive catalysts.

Keywords

Healthcare Data, Commercial Intelligence, SaaS, Life Sciences, Provider, Healthcare IT, Data Analytics, SEC Filing, 10-K, Financial Performance, Goodwill Impairment, Net Dollar Retention, Customer Churn, Macroeconomic Impact, Corporate Governance, Risk Management, AI Technology, Data Privacy, Cybersecurity, Stock Repurchase